article thumbnail

STAT+: Pretzel Therapeutics, eyeing diseases caused by broken mitochondria, launches with $72.5 million

STAT News

In the life sciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. The company is developing treatments for diseases caused by broken mitochondria — the main energy source for human cells.

article thumbnail

AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

pharmaphorum

billion for MedCo, clearly thinking it can succeed where its rivals have so far failed and build inclisiran into a blockbuster brand if it gets approved by the FDA, which is due to deliver a verdict sometime before the end of this year. Novartis paid a hefty $9.7

Drugs 66
article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Sooter has also found success in industry, leading and bringing together the work of different teams of researchers at NeuBase to help drive the company’s goal of developing cures and treatments for genetic diseases, including Huntington’s Disease. She says, “It’s been a lot of fun; it’s a decision I’m glad I made.”.